# Illumina **Source:** https://geo.sig.ai/brands/illumina **Vertical:** Life Sciences & BioTech **Subcategory:** Genomics & Sequencing **Tier:** Leader **Website:** illumina.com **Last Updated:** 2026-04-14 ## Summary World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and population-scale sequencing. ## Company Overview Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applications. The company's sequencing-by-synthesis (SBS) chemistry and NovaSeq, NextSeq, and MiSeq instrument platforms have become the standard infrastructure for genomic research, clinical oncology, reproductive health, and infectious disease diagnostics worldwide.\n\nIllumina's business model combines high-margin consumable sales (flow cells, reagent kits) with instrument placements, creating a razor-and-blades recurring revenue structure. Its clinical sequencing segment showed accelerating growth in 2025, with clinical consumables revenue up 20% year-over-year in Q4. The company is expanding into spatial transcriptomics and multi-omics with new instruments unveiled at AGBT 2025, broadening its addressable market.\n\nIllumina reported $4.34 billion in FY2025 revenue and guides to $4.5–$4.6 billion for FY2026, with non-GAAP operating margins of ~23%. Having divested Grail (its liquid biopsy subsidiary) following regulatory pressure, Illumina is refocused on its core sequencing franchise and positioned to benefit from continued clinical adoption of genomic medicine. ## Frequently Asked Questions ### What market share does Illumina hold in DNA sequencing? Illumina holds approximately 80% global market share in next-generation sequencing, making its platforms the industry standard for both research and clinical genomics. ### What was Illumina's 2025 revenue and 2026 outlook? Illumina reported $4.34 billion in FY2025 revenue (flat year-over-year) and guides to $4.5–$4.6 billion in FY2026 with ~23% non-GAAP operating margins. ### What new products is Illumina launching? Illumina unveiled a new spatial transcriptomics platform at AGBT 2025, expanding its multi-omics portfolio beyond traditional short-read sequencing. ### What is Illumina's NovaSeq platform and who uses it? NovaSeq is Illumina's high-throughput sequencing platform designed for large-scale genomics applications including population genomics studies, clinical oncology, and large biobank sequencing. It can sequence a human genome for under $200 and is used by major academic medical centers, biotech companies, and national genomics programs worldwide. ### How does Illumina's sequencing technology work? Illumina uses sequencing-by-synthesis (SBS) chemistry, where fluorescently labeled nucleotides are incorporated one by one into growing DNA strands. A camera detects the fluorescent signals to determine the sequence. This approach enables massively parallel sequencing of billions of DNA fragments simultaneously. ### What is Illumina's GRAIL division and why did it attract regulatory scrutiny? GRAIL develops multi-cancer early detection blood tests using Illumina's sequencing technology. Illumina's 2021 acquisition of GRAIL attracted antitrust challenges from the FTC and European Commission, ultimately resulting in a forced divestiture order. Illumina divested GRAIL in 2024, though GRAIL continues as an independent company. ### What are Illumina's main clinical applications? Illumina's sequencing platforms enable non-invasive prenatal testing (NIPT), oncology tumor profiling, pharmacogenomics, rare disease diagnosis, and infectious disease surveillance. Clinical laboratory customers use Illumina instruments to offer genomic testing services to patients and healthcare providers. ### Who are Illumina's main competitors in next-generation sequencing? Pacific Biosciences (long-read sequencing), Oxford Nanopore Technologies (portable nanopore sequencing), and BGI/MGI (lower-cost short-read sequencing) are Illumina's primary competitors. While Illumina dominates short-read sequencing, long-read platforms from PacBio and Nanopore are gaining adoption for applications requiring full genome assembly and structural variant detection. ### What are Illumina's primary sequencing platforms? Illumina's sequencing platform portfolio includes the NovaSeq X (ultra-high throughput for population genomics and clinical labs), the NextSeq (mid-throughput for research), the MiSeq (benchtop for targeted sequencing), and DRAGEN (on-instrument bioinformatics processing) — covering applications from single-gene panels to whole-genome sequencing. ### What clinical applications rely on Illumina's sequencing? Illumina's sequencing underpins non-invasive prenatal testing (NIPT), hereditary cancer gene panel testing, tumor genomic profiling for oncology treatment decisions, rare disease diagnosis through clinical whole-genome sequencing, and pathogen genomic surveillance including COVID-19 variant tracking. ### What was Illumina's GRAIL acquisition and why was it blocked? Illumina acquired GRAIL, a liquid biopsy cancer detection company, for $8 billion in 2021. The acquisition was blocked by European and US regulators who ruled that Illumina's market position in sequencing gave it unfair advantage in the GRAIL liquid biopsy market. Illumina was forced to divest GRAIL in 2024, taking a significant financial write-down. ### What is the cost to sequence a human genome on Illumina's platform? The NovaSeq X can deliver whole human genome sequencing at approximately $200 per genome at scale — a dramatic decline from the $1,000 per genome milestone in 2014 and the $3 billion cost of the original Human Genome Project, enabling clinical-scale population genomics. ### What competition does Illumina face? Illumina faces growing competition from Oxford Nanopore Technologies (long-read sequencing), Pacific Biosciences (HiFi long reads), and MGI (a Chinese competitor offering lower-cost short-read instruments) — with long-read technologies increasingly competitive for applications requiring structural variant detection and phasing. ## Tags b2b, global, public, enterprise, healthtech, analytics, hardware, platform, fortune500 --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*